Rocket-AF
Investigation questions Xarelto trial data accuracy
February 4, 2016Medical Communications BMJ, Bayer, INR, Johnson & Johnson, New England Journal of Medicine, Rocket-AF, Xarelto, blood clotting, rivaroxaban
The ROCKET-AF trial, the pivotal trial of the top-selling anti-clotting drug Xarelto, could have been undermined by unreliable results from …
Latest content
Medtronic secures CE Mark for new cardiac pacing portfolio
October 30, 2026
Dermatology leader Doncker is new Onicor CEO
October 29, 2026
October 28, 2026
